Radiation Treatment ~ Breast Cancer
~ Genetics of Breast & Ovarian Cancer

List was last updated on Dec 1, 2019 @ 8:19 am.


    • Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
    • Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos RDNG, Cotti GC, Hoff PM, Fragoso MCBV, Estevez-Diz MDP.
    • Fam Cancer. 2019 Nov 20. doi: 10.1007/s10689-019-00153-5. [Epub ahead of print]
    • Prophylactic breast irradiation reduces background parenchymal enhancement (BPE) on MRI: A secondary analysis.
    • Ben-David MA, Corn BW, Evron E, Goldberg H, Pfeffer RM, Abdah-Bortnyak R, Matceyevsky D, Weinstein Y, Golan O, Sklair-Levy M.
    • Breast. 2019 Nov 6;49:70-73. doi: 10.1016/j.breast.2019.10.011. [Epub ahead of print]
    • Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
    • Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.
    • Pharmaceuticals (Basel). 2019 Oct 15;12(4). pii: E155. doi: 10.3390/ph12040155.
    • Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer.
    • Watt GP, Reiner AS, Smith SA, Stram DO, Capanu M, Malone KE, Lynch CF, John EM, Knight JA, Mellemkjær L, Bernstein L, Brooks JD, Woods M, Liang X, Haile RW, Riaz N, Conti DV, Robson M, Duggan D, Boice JD Jr, Shore RE, Tischkowitz M, Orlow I, Thomas DC, Concannon P, Bernstein JL.
    • JAMA Netw Open. 2019 Sep 4;2(9):e1912259. doi: 10.1001/jamanetworkopen.2019.12259.
    • Participation in a Novel Trial Assessing Prophylactic Breast Irradiation: The Importance of Input from the Radiation Oncologist.
    • Evron E, Goldberg H, Ben-David MA, Corn BW.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 10. pii: S0360-3016(19)33636-3. doi: 10.1016/j.ijrobp.2019.08.004. [Epub ahead of print]
    • The implications of genetic testing on radiotherapy decisions: a guide for radiation oncologists.
    • Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 2. pii: S0360-3016(19)33530-8. doi: 10.1016/j.ijrobp.2019.07.026. [Epub ahead of print]
    • Review
    • Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    • van den Broek AJ, Schmidt MK, van 't Veer LJ, Oldenburg HSA, Rutgers EJ, Russell NS, Smit VTHBM, Voogd AC, Koppert LB, Siesling S, Jobsen JJ, Westenend PJ, van Leeuwen FE, Tollenaar RAEM.
    • Ann Surg. 2019 Aug;270(2):364-372. doi: 10.1097/SLA.0000000000002804.
    • Chromosomal radiosensitivity of triple negative breast cancer patients.
    • Francies FZ, Herd O, Cairns A, Nietz S, Murdoch M, Slabbert J, Claes KB, Vral A, Baeyens A.
    • Int J Radiat Biol. 2019 Jul 26:1-30. doi: 10.1080/09553002.2019.1649502. [Epub ahead of print]
    • Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
    • Vallard A, Magné N, Guy JB, Espenel S, Rancoule C, Diao P, Deutsch E, Rivera S, Chargari C.
    • Br J Radiol. 2019 May;92(1097):20170657. doi: 10.1259/bjr.20170657. Epub 2019 Feb 27.
    • Review
    • Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI).
    • Ahmed F, Christos PJ, Singh P, Parashar B, Wernicke AG.
    • Am J Clin Oncol. 2019 Apr 9. doi: 10.1097/COC.0000000000000542. [Epub ahead of print]
    • Contralateral breast irradiation in BRCA carriers: the conundrum of prophylactic versus early treatment.
    • Poortmans PMP, Kaidar-Person O.
    • Ann Oncol. 2019 Mar 1;30(3):348-350. doi: 10.1093/annonc/mdz014.
    • Research news, Editorial
    • Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.
    • Evron E, Ben-David AM, Goldberg H, Fried G, Kaufman B, Catane R, Pfeffer MR, Geffen DB, Chernobelsky P, Karni T, Abdah-Bortnyak R, Rosengarten O, Matceyevsky D, Inbar M, Kuten A, Corn BW.
    • Ann Oncol. 2019 Mar 1;30(3):412-417. doi: 10.1093/annonc/mdy515.

    Editorial:

    Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer?

    • Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    • Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.
    • Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
    • Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery.
    • Strach MC, Prasanna T, Kirova YM, Alran S, O'Toole S, Beith JM, Poortmans P, McNeil CM, Carroll S.
    • Crit Rev Oncol Hematol. 2019 Feb;134:10-21. doi: 10.1016/j.critrevonc.2018.11.007. Epub 2018 Nov 30.
    • Review
    • Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report.
    • Wolfe AR, Jain R, Pawlik TM, Walker J, Williams TM.
    • Adv Radiat Oncol. 2018 Sep 7;4(1):10-14. doi: 10.1016/j.adro.2018.08.025. eCollection 2019 Jan-Mar.
    • Unusual recurrence of breast cancer in a BRCA-variant patient after fat grafting.
    • Skendelas JP, Lee C, Mangino A, Carson WE 3rd.
    • Clin Case Rep. 2018 Oct 31;6(12):2457-2462. doi: 10.1002/ccr3.1861. eCollection 2018 Dec.
    • Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
    • Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, Cardenas PY, Zakalik D.
    • Clin Breast Cancer. 2018 Oct;18(5):e1229-e1235. doi: 10.1016/j.clbc.2017.12.014. Epub 2017 Dec 30.
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies.
    • Deycmar S, Pruschy M.
    • Int J Part Ther. 2018 Summer;5(1):133-139. doi: 10.14338/IJPT-18-00020.1. Epub 2018 Sep 21.
    • Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    • Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A.
    • Clin Breast Cancer. 2018 Feb;18(1):e107-e113. doi: 10.1016/j.clbc.2017.07.016. Epub 2017 Aug 1.
    • Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    • Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.
    • Int J Hyperthermia. 2018 Feb;34(1):39-48. doi: 10.1080/02656736.2017.1324642. Epub 2017 May 19.
    • The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1+/- lymphoblastoid cells.
    • Bourton EC, Ahorner PA, Plowman PN, Zahir SA, Al-Ali H, Parris CN.
    • J Cancer. 2017 Oct 23;8(19):4048-4056. doi: 10.7150/jca.21338. eCollection 2017.
    • Severe Late Toxicity After Adjuvant Breast Radiotherapy in a Patient with a Germline Ataxia Telangiectasia Mutated Gene: Future Treatment Decisions.
    • Dosani M, Schrader KA, Nichol A, Sun S, Shenkier T, Lohn Z, Aubertin G, Tyldesley S.
    • Cureus. 2017 Jul 11;9(7):e1458. doi: 10.7759/cureus.1458.
    • A Summary of Recent Oncology Research: Changes to the National Cancer Institute's PDQ Information.
    • [No author given]
    • J Natl Cancer Inst. 2017 Apr 13;109(4). pii: djx080. doi: 10.1093/jnci/djx080. Print 2017 Apr.
    • News

    Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.

    • Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.
    • Chen F, Pu F.
    • Onco Targets Ther. 2017 Apr 6;10:2009-2016. doi: 10.2147/OTT.S123803. eCollection 2017.
    • Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.
    • Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.
    • Oncol Rep. 2017 Mar;37(3):1379-1386. doi: 10.3892/or.2017.5407. Epub 2017 Jan 25.
    • Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.
    • Gewirtz DA, Alotaibi M, Yakovlev VA, Povirk LF.
    • Radiat Res. 2016 Oct;186(4):327-332. Epub 2016 Sep 2.
    • Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity.
    • Dorling L, Barnett GC, Michailidou K, Coles CE, Burnet NG, Yarnold J, Elliott RM, Dunning AM, Pharoah PD, West CM.
    • Clin Cancer Res. 2016 Mar 15;22(6):1413-20. doi: 10.1158/1078-0432.CCR-15-1080. Epub 2015 Oct 28.
    • Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer.
    • Borrego-Soto G, Ortiz-López R, Rojas-Martínez A.
    • Genet Mol Biol. 2015 Dec;38(4):420-32. doi: 10.1590/S1415-475738420150019. Epub 2015 Nov 24.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: CHEK2 and adjuvant radiation therapy

    • Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
    • Drooger J, Akdeniz D, Pignol JP, Koppert LB, McCool D, Seynaeve CM, Hooning MJ, Jager A.
    • Breast Cancer Res Treat. 2015 Nov;154(1):171-80.

    News:

    A Summary of Recent Oncology Research: Changes to the National Cancer Institute's PDQ Information.

    • BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
    • Kan C, Zhang J.
    • Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):281-93. doi: 10.1016/j.ijrobp.2015.05.037.
    • Review
    • BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review.
    • Hallam S, Govindarajulu S, Huckett B, Bahl A.
    • Clin Oncol (R Coll Radiol). 2015 Sep;27(9):527-35. doi: 10.1016/j.clon.2015.06.001. Epub 2015 Jun 22.
    • Review

    Comment

    Is Breast-conserving Therapy Really a Good Option for BRCA1/2 Mutation Carriers?

    • Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
    • Chiang HC, Elledge R, Larson P, Jatoi I, Li R, Hu Y.
    • Breast Cancer (Auckl). 2015 Jun 2;9:25-9. doi: 10.4137/BCBCR.S26774. eCollection 2015.
    • Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: a review.
    • Bernier J, Poortmans P.
    • Breast. 2015 Apr;24(2):100-6. doi: 10.1016/j.breast.2014.12.003. Epub 2014 Dec 31.
    • Review
    • Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    • Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.
    • BMC Cancer. 2015 Mar 3;15:89. doi: 10.1186/s12885-015-1090-7.
    • Radiation therapy in the locoregional treatment of triple-negative breast cancer.
    • Moran MS.
    • Lancet Oncol. 2015 Mar;16(3):e113-e122. doi: 10.1016/S1470-2045(14)71104-0.
    • Review
    • An update on PARP inhibitors for the treatment of cancer.
    • Benafif S, Hall M.
    • Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015.
    • Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature.
    • Drooger JC, Hooning MJ, Seynaeve CM, Baaijens MH, Obdeijn IM, Sleijfer S, Jager A.
    • Cancer Treat Rev. 2015 Feb;41(2):187-196. doi: 10.1016/j.ctrv.2014.12.002. Epub 2014 Dec 8.
    • Review
    • The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation.
    • Huszno J, Budryk M, Kołosza Z, Nowara E.
    • Contemp Oncol (Pozn). 2015;19(1):72-6. doi: 10.5114/wo.2015.50014. Epub 2015 Mar 26.
    • [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
    • Pernin V, Mégnin-Chanet F, Pennaneach V, Fourquet A, Kirova Y, Hall J.
    • Cancer Radiother. 2014 Dec;18(8):790-8; quiz 799-802. doi: 10.1016/j.canrad.2014.05.012. Epub 2014 Oct 17.
    • Review, [Article in French]
    • Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.
    • Feng FY, Speers C, Liu M, Jackson WC, Moon D, Rinkinen J, Wilder-Romans K, Jagsi R, Pierce LJ.
    • Breast Cancer Res Treat. 2014 Aug;147(1):81-94. doi: 10.1007/s10549-014-3085-5. Epub 2014 Aug 8.
    • Active approach for breast cancer genetic counseling during radiotherapy: long-term psychosocial and medical impact.
    • Baars JE, Bleiker EM, van Riel E, Rodenhuis CC, Velthuizen ME, Schlich KJ, Ausems MG.
    • Clin Genet. 2014 Jun;85(6):524-31. doi: 10.1111/cge.12335. Epub 2014 Feb 4.
    • [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    • Gaziev AI.
    • Radiats Biol Radioecol. 2014 May-Jun;54(3):229-40.
    • [Article in Russian]
    • Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations.
    • Park H, Choi DH, Noh JM, Huh SJ, Park W, Nam SJ, Lee JE.
    • Int J Radiat Biol. 2014 Jan;90(1):90-4. doi: 10.3109/09553002.2013.835504. Epub 2013 Sep 19.
    • Management of male breast cancer in the United States: a surveillance, epidemiology and end results analysis.
    • Fields EC, DeWitt P, Fisher CM, Rabinovitch R.
    • Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):747-52. doi: 10.1016/j.ijrobp.2013.07.016.
    • The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
    • Huszno J, Budryk M, Kołosza Z, Nowara E.
    • Oncology. [2013 Nov;]85(5):278-82. doi: 10.1159/000354834. Epub 2013 Nov 6.
    • Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients--potential differential effects by radiotherapy?
    • Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D, Chang-Claude J.
    • Breast. 2013 Oct;22(5):817-23. doi: 10.1016/j.breast.2013.02.008. Epub 2013 Mar 13.
    • Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody.
    • Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, Deweese TL, Sgouros G.
    • Mol Cancer Ther. 2013 Oct;12(10):2043-54. doi: 10.1158/1535-7163.MCT-13-0108. Epub 2013 Jul 19.
    • Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study Report.
    • Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD Jr, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen JH, Mellemkjaer L, Liang X, Diep AT, Borg A, Concannon P, Haile RW; WECARE Study Collaborative.
    • Eur J Cancer. 2013 Sep;49(14):2979-85. doi: 10.1016/j.ejca.2013.04.028. Epub 2013 May 21.
    • Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
    • Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK.
    • J Nucl Med. 2013 Jun;54(6):913-21. doi: 10.2967/jnumed.112.111534. Epub 2013 Apr 5.
    • DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.
    • Mladenov E, Magin S, Soni A, Iliakis G.
    • Front Oncol. 2013 May 10;3:113. doi: 10.3389/fonc.2013.00113. eCollection 2013.
    • Variation in telangiectasia predisposing genes is associated with overall radiation toxicity.
    • Tanteles GA, Murray RJ, Mills J, Barwell J, Chakraborti P, Chan S, Cheung KL, Ennis D, Khurshid N, Lambert K, Machhar R, Meisuria M, Osman A, Peat I, Sahota H, Woodings P, Talbot CJ, Symonds RP.
    • Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):1031-6. doi: 10.1016/j.ijrobp.2012.02.018. Epub 2012 Jun 6.
    • Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier.
    • Chiang HC, Nair SJ, Yeh IT, Santillan AA, Hu Y, Elledge R, Li R.
    • Exp Hematol Oncol. 2012 Oct 8;1(1):31. doi: 10.1186/2162-3619-1-31.
    • Options in breast cancer local therapy: who gets what?
    • Jatoi I.
    • World J Surg. 2012 Jul;36(7):1498-502. doi: 10.1007/s00268-012-1530-3.
    • Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia.
    • Byrd PJ, Srinivasan V, Last JI, Smith A, Biggs P, Carney EF, Exley A, Abson C, Stewart GS, Izatt L, Taylor AM.
    • Br J Cancer. 2012 Jan 17;106(2):262-8. doi: 10.1038/bjc.2011.534. Epub 2011 Dec 6.
    • Is there a role for postmastectomy radiation therapy in ductal carcinoma in situ?
    • Chadha M, Portenoy J, Boolbol SK, Gillego A, Harrison LB.
    • Int J Surg Oncol. 2012;2012:423520. doi: 10.1155/2012/423520. Epub 2012 Jun 13.